Inc Ransom ransomware group lists glenmarkpharma.com on its leak site

• Ransomware group: Inc Ransom
• Country: India
• Sector: Healthcare
• Announcement date: March 25, 2026

Inc Ransom claims attack on Glenmark Pharmaceuticals

The Inc Ransom ransomware group has listed the Indian pharmaceutical company Glenmark Pharmaceuticals on its dedicated leak site. According to an announcement published on March 25, 2026, the threat actor group claims to have successfully targeted the organization. This listing serves as a public notification from the group, asserting that they have gained unauthorized access to the company's internal systems and operational data.

Ransomware leak sites function as a platform for cybercriminal groups to exert pressure on their victims. These sites are used to host announcements regarding successful breaches, often accompanied by countdown timers or specific demands. In many cases, these platforms are used to shame organizations that refuse to pay a ransom, creating a public record of the incident that can lead to significant reputational damage and secondary security risks.

The current announcement remains active on the group's leak portal. While the group has made these claims, the incident highlights the ongoing threat posed by ransomware operations to large-scale global enterprises. Such attacks often involve complex stages, from initial infiltration to data exfiltration, aimed at maximizing the leverage held by the attackers during negotiations.

Details of the claimed data breach

Regarding the specific content of the breach, the Inc Ransom group has not provided any details concerning the nature or volume of the leaked data. No specific information was provided regarding the total size of the data or the exact file count involved in the incident. The group's post does not include a specific ransom demand at this time.

Although the group has not specified the types of files stolen, the announcement does include certain sensitive information related to the company's structure. The post contains contact information for the company's senior executives and various corporate communication channels. The presence of such information in a public leak post can be used by attackers to facilitate further social engineering or targeted communication attempts.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a global pharmaceutical company that was founded in 1977. The organization is headquartered in Mumbai, India. The company specializes in a wide range of activities within the medical field, including the research, development, manufacturing, and marketing of pharmaceutical products. Their work spans across various therapeutic areas, making them a significant player in the global healthcare sector.

Risk assessment and industry implications

The situation involving Glenmark Pharmaceuticals carries several potential risks, particularly due to the tactics employed by the Inc Ransom group. This group is known for utilizing double-extortion tactics. In a double-extortion scenario, attackers do not merely encrypt an organization's data to disrupt operations; they also steal sensitive information before the encryption process begins. This allows them to threaten the public release of the data if the ransom is not met, thereby increasing the pressure on the victim.

Because Glenmark Pharmaceuticals operates within the healthcare sector, the potential for a data breach presents unique challenges. Organizations in this sector handle highly sensitive information, and breaches can create significant difficulties regarding patient privacy and regulatory compliance. The exposure of sensitive commercial or personal data can lead to long-term consequences for both the company and the individuals whose information may be at risk.

Furthermore, such incidents often lead to secondary risks. These include the possibility of targeted phishing attacks directed at the company's employees and business partners, as attackers may use the information gathered to craft highly convincing fraudulent communications. Such attacks aim to exploit the trust established through legitimate business channels. Additionally, the leak of data can have a profound impact on the organization's reputation, potentially affecting its standing with stakeholders, partners, and the public.

To defend against such threats, organizations in the healthcare and pharmaceutical sectors typically focus on robust security frameworks. This includes implementing strict access controls, maintaining comprehensive logging and monitoring to detect unauthorized access, and conducting regular security awareness training to help employees recognize phishing attempts. Protecting the integrity of operational and personal data remains a critical priority for global pharmaceutical entities.